Skip to main content
Signal8

Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica

$EVGNPress releaseJun 2, 2026, 7:00 AM ETRead the release

Evogene announced the successful completion of the first-in-human Phase 1 clinical study of BMC128, a live bacterial product developed by its subsidiary Biomica, in combination with Nivolumab for advanced solid tumors. The open-label study enrolled 11 patients who had progressed on prior anti-PD-1 therapy. The trial met its primary endpoint of favorable safety and tolerability, with no dose-limiting toxicities observed. Preliminary efficacy signals included one partial response and five patients achieving stable disease beyond the 16-week combination period.

Key figures

Drug Name
BMC128 (now LS-LBP-002)
Phase Of Trial
Phase 1
Partial responses
1
Patients enrolled
11
Patients on maintenance
2
Stable disease patients
5

AI analysis

The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.

    EVGN: Evogene Announces Successful Completion of Phase 1 Clinical Study of BMC128, a Rationally Designed Live Bacterial Product, in Combination with Nivolumab by its Subsidiary Biomica — AI Analysis | Signal8